Results of the first-in-man, dose-escalation study of a prostate-specific membrane antigen antibody–drug conjugate (PSMA ADC) have been reported. This therapy is designed to bind to PSMA+ cells specifically, internalize and release the drug into the cell. PSMA ADC has shown promise in preclinical models. In this study, the conjugate showed antitumour activity at doses ≤2.5 mg/kg in a cohort of 52 men with metastatic castration-resistant prostate cancer (mCRPC) and toxic effects were acceptable. Thus, this new therapy has promise for treating mCRPC.
References
Original article
Petrylak, D. P. et al. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. Prostate https://doi.org/10.1002/pros.23765 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stone, L. PSMA ADC shows promise in advanced disease. Nat Rev Urol 16, 206 (2019). https://doi.org/10.1038/s41585-019-0161-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-019-0161-y
